Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced it will showcase 10 studies
highlighting its advancements in oncology and reproductive genetic
testing at the National Society of Genetic Counselors (NSGC) 43rd
Annual Conference, which will take place from Sept. 17-21, 2024, in
New Orleans, LA. The research will highlight the value of genetic
and genomic testing in patient care and will cover the company’s
MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen,
Prequel Prenatal Screen and Foresight Carrier Screen.
“At Myriad, we’re committed to partnering with genetic
counselors in an effort to make genetic testing more accessible,
affordable and easier to use for all patient populations,” said
Susan Manley, Senior Vice President of Medical Services, Myriad
Genetics. “We’re excited to share our new research with the genetic
counselor community at this year’s NSGC Conference and to showcase
how our latest advancements may help better inform personalized
care and improve outcomes for patients.”
Myriad’s latest innovations and support services will be on
display at booth #119 and through a series of poster presentations
at the conference.
Myriad’s Presentation Schedule
Wednesday, Sept. 18, 2024, from 12:15-2:00pm and 5:45-7:00pm
CDT
Poster CAN91: Age at Diagnosis of Breast Cancer
for Women with Pathogenic Variants in BARD1, RAD51C, and
RAD51DSummary: This study shows that the median
age of breast cancer diagnosis with pathogenic variants (PVs) in
BARD1, RAD51C, and RAD51D is similar to that of other breast cancer
genes. Additionally, it shows that a significant number of PV
carriers are diagnosed prior to the recommended screening age of 40
years.
Poster PRE323: Outcomes in pregnancies that
screened positive for rare autosomal aneuploidies (RAAs)
Summary: By linking prenatal cell-free DNA results
to insurance claims data, this study provides evidence that
RAA-screen positive patients have higher rates of miscarriage and
preterm birth as compared to RAA-screen negative patients.
Poster PRE333: Complications and outcomes of
pregnancies screening positive for microdeletions 22q11.2, 15q11.2,
1p36, 4p, or 5pSummary: This study shows that
microdeletion screen-positive pregnancies may experience higher
rates of ultrasound abnormalities and pregnancy complications.
Poster PRE347: Validation of fetal and maternal
recessive disease genotyping with FirstGene: a combined,
non-invasive prenatal cfDNA assay for fetal aneuploidy, recessive
diseases, and serological screeningSummary: This
study indicates that the FirstGene screen accurately identifies
fetal SNV and INDELs for recessive conditions.
Poster PRE349: Validation of fetal and maternal
spinal muscular atrophy (SMA) and hemoglobin (Hb) Bart’s screening
with FirstGene, a combined, non-invasive prenatal cfDNA assay for
fetal aneuploidy, recessive diseases, and serological screening
Summary: This study indicates that the FirstGene
screen accurately identifies maternal and fetal SMA and Hb Bart’s
disease status.
Poster PRE351: Validation of fetal RHD copy
number calling in FirstGene, a combined, non-invasive prenatal
cfDNA assay for fetal aneuploidy, recessive diseases, and
serological screeningSummary: This study indicates
that the FirstGene assay accurately determines fetal RHD copy
number in RhD-negative pregnant patients.
Thursday, Sept. 19, 2024, from 12:00-3:00pm and 4:30-6:30pm
CDT
Poster PRE324: A comparison of carrier rates
derived from different data sourcesSummary: This
study shows high concordance in carrier rates between Myriad’s
database and gnomAD data.
Poster PRE344: Investigating cancer diagnosis
codes after atypical findings on noninvasive prenatal cell-free DNA
(pcfDNA) screeningSummary: This study indicates
that patients with an autosomal monosomy or multiple aneuploidies
on pcfDNA have a higher risk of a cancer diagnosis than those
without.
Poster PRE348: Validation of fetal aneuploidy
detection with FirstGene: a combined, non-invasive prenatal cfDNA
assay for fetal aneuploidy, recessive diseases, and serological
screeningSummary: This study indicates that fetal
aneuploidy screening on the FirstGene assay is comparable to that
of standalone WGS-based pcfDNA screening with fetal fraction
amplification.
Lunch Symposium: At 12:45pm CDT, Myriad will
host a lunch symposium titled ‘How genetic counselors can integrate
breast cancer risk assessment programs into surgical, primary care,
OB/GYN, and imaging clinics’, moderated by Myriad’s Susan
Manley.
Myriad will also have a virtual presentation, Characteristics
and Cancer Incidence in MITF p.E318K Carriers, available for
viewing on the NSGC online experience platform. This study shows
that MITF carriers have an increased risk of melanoma, but not
renal cancer, as several other studies have suggested.
For more information about Myriad’s presence at NSGC, please
visit: https://myriad.com/nsgc2024/. Updates will also be shared
across Myriad’s LinkedIn and X channels throughout the
conference.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the company's commitment to partnering with
genetic counselors in an effort to make genetic testing more
accessible, affordable and easier to use for all patient
populations and how the company’s latest advancement may help
better inform personalized care and improve outcomes for patients.
These “forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on February 28, 2024, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024